MLTX

53.57

0.00% 0.00

Vorhandelsmarkt: 53.57

Moonlake Immunotherapeutics (MLTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MLTX? Forum Prognose

Schlusskurs vom Vortag:

$53.57

Offen:

$53.76

24-Stunden-Volumen:

341.71K

Relative Volume:

0.68

Marktkapitalisierung:

$3.40B

Einnahmen:

Nettoeinkommen (Verlust:

$-145.21M

KGV:

-23.29

EPS:

-2.3

Netto-Cashflow:

$-140.12M

1W Leistung:

+7.85%

1M Leistung:

+23.15%

6M Leistung:

+13.71%

1J Leistung:

+19.84%

1-Tages-Spanne:

$52.65

$54.26

1-Wochen-Bereich:

$49.98

$54.63

52-Wochen-Spanne:

$31.42

$58.26

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Firmenname

Moonlake Immunotherapeutics

Sektor

Healthcare (1161)

Branche

Biotechnology (653)

Telefon

41 41 510 8022

Adresse

DORFSTRASSE 29, ZUG

Mitarbeiter

100

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

MLTX's Discussions on Twitter

Vergleichen Sie MLTX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MLTX Moonlake Immunotherapeutics	53.57	3.15B	0	-145.21M	-140.12M	-2.30
VRTX Vertex Pharmaceuticals Inc	470.13	119.21B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	560.93	59.16B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	325.28	40.57B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	571.23	34.02B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	295.59	29.19B	3.81B	-644.79M	-669.77M	-6.24

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-19	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-03-18	Eingeleitet	RBC Capital Mkts	Outperform
2025-01-17	Hochstufung	Goldman	Neutral → Buy
2024-11-05	Fortgesetzt	Wedbush	Outperform
2024-08-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-25	Eingeleitet	Oppenheimer	Outperform
2024-04-02	Eingeleitet	Goldman	Neutral
2024-02-15	Eingeleitet	Wolfe Research	Outperform
2023-12-08	Eingeleitet	Citigroup	Buy
2023-11-02	Eingeleitet	Stifel	Buy
2023-09-14	Herabstufung	Bryan Garnier	Buy → Neutral
2023-08-31	Eingeleitet	Needham	Buy
2023-06-15	Eingeleitet	Barclays	Equal Weight
2023-05-01	Eingeleitet	Guggenheim	Buy
2023-03-22	Eingeleitet	Wedbush	Outperform
2023-03-09	Eingeleitet	BTIG Research	Buy
2023-02-14	Eingeleitet	Cantor Fitzgerald	Overweight
2023-02-02	Eingeleitet	Bryan Garnier	Buy
2022-11-11	Eingeleitet	Jefferies	Buy
2022-08-25	Eingeleitet	SVB Leerink	Outperform
2022-07-21	Eingeleitet	H.C. Wainwright	Buy
2022-07-07	Eingeleitet	Cowen	Outperform

Alle ansehen

Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten

Jul 22, 2025

MoonLake Immunotherapeutics Stock Analysis and ForecastRapidly expanding wealth - jammulinksnews.com

Jul 22, 2025

What analysts say about MoonLake Immunotherapeutics stockOutstanding trading profits - jammulinksnews.com

Jul 22, 2025

Is MoonLake Immunotherapeutics a good long term investmentSky-high return potential - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

What drives MoonLake Immunotherapeutics stock pricePhenomenal capital appreciation - Autocar Professional

Jul 21, 2025

Jul 17, 2025

(MLTX) Trading Advice - news.stocktradersdaily.com

Jul 17, 2025

MoonLake Immunotherap Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily

Jul 17, 2025

Jul 15, 2025

What makes MoonLake Immunotherapeutics stock price move sharplyFree Investment Risk Control - Newser

Jul 15, 2025

Why MoonLake Immunotherapeutics stock attracts strong analyst attentionFree Stock Market Insider Analysis - Newser

Jul 15, 2025

How MoonLake Immunotherapeutics stock performs during market volatilityQuick Profit Idea Stream - Newser

Jul 15, 2025

MoonLake Immunotherap Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily

Jul 15, 2025

Jul 10, 2025

Merck made $3B+ offer for MoonLake earlier this yearreport - MSN

Jul 10, 2025

MoonLake Immunotherap Getting Closer To Key Technical Benchmark - Investor's Business Daily

Jul 10, 2025

Jul 07, 2025

MoonLake Immunotherapeutics Director Makes a Major Stock Move! - TipRanks

Jul 07, 2025

Jun 28, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Challenges - geneonline.com

Jun 28, 2025

Jun 19, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Sector Challenges - geneonline.com

Jun 19, 2025

Jun 16, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Developments - geneonline.com

Jun 16, 2025

Jun 15, 2025

Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com

Jun 15, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Developments - geneonline.com

Jun 15, 2025

Jun 13, 2025

MoonLake Immunotherapeutics’ SWOT analysis: nanobody firm’s stock poised for pivotal phase III data - Investing.com South Africa

Jun 13, 2025

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga

Jun 13, 2025

IIH interview: Matthias Bodenstedt discusses MoonLake’s capital raising journey, the appeal of SLK and plans for the future - Investors in Healthcare

Jun 13, 2025

MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating - TipRanks

Jun 13, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Shifts - geneonline.com

Jun 13, 2025

Jun 12, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Focus on Inflammatory Disease Treatments - geneonline.com

Jun 12, 2025

Jun 10, 2025

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN

Jun 10, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Focus - geneonline.com

Jun 10, 2025

Jun 09, 2025